Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRISDELLE vs ABILIFY ASIMTUFII
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
Schizophrenia,Maintenance monotherapy treatment of bipolar I disorder
8 mg orally once daily, taken at bedtime.
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole is formed primarily by CYP3A4 and CYP2D6; exhibits significant interindividual variability due to CYP2D6 polymorphism.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
>99% bound to serum albumin.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
4.9 L/kg, indicating extensive extravascular distribution.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
Intramuscular: 100% (as a depot suspension).
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
No dosage adjustment required for patients with renal impairment (Cr Cl ≥15 m L/min). Insufficient data for patients with end-stage renal disease (Cr Cl <15 m L/min).
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh class A or B). Use with caution in severe hepatic impairment (Child-Pugh class C) as experience is limited.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for use in pediatric patients. Safety and efficacy have not been established.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Use with caution due to increased sensitivity to orthostatic hypotension and sedative effects. Consider lower starting doses (300 mg orally equivalent) but no specific dose adjustment for the injectable form is recommended.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Increased mortality in elderly patients with dementia-related psychosis; cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome (NMS); tardive dyskinesia; metabolic changes (hyperglycemia/diabetes mellitus, dyslipidemia, weight gain); pathological gambling and other compulsive behaviors; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; potential for additive effects with alcohol or CNS depressants; injection site reactions; risk of extrapyramidal symptoms; suicidal thoughts/behaviors.
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
Known hypersensitivity to aripiprazole or any component of the formulation; concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin)
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
Avoid grapefruit juice and grapefruit products as they may increase aripiprazole levels. Alcohol should be limited or avoided due to additive CNS depression and increased risk of sedation.
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Advise use only if benefit outweighs risk.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
Excreted in human milk; limited data. M/P ratio not established. Decision to discontinue nursing or drug based on importance of drug to mother. Use caution.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
No recommended dose adjustments in pregnancy; consider pharmacokinetic changes (e.g., increased clearance) may require titration, but evidence lacking.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
ABILIFY ASIMTUFII (aripiprazole) is a long-acting injectable suspension for intramuscular use. Administer only by a healthcare professional. Observe patient for 2 hours post-injection due to risk of post-injection delirium/sedation syndrome. Requires 3 consecutive daily doses of oral aripiprazole (10-20 mg) before initiation to confirm tolerability. Dosing: 441 mg IM monthly (equates to 400 mg aripiprazole). Do not substitute with other aripiprazole formulations on a mg-per-mg basis. Contraindicated in patients with known hypersensitivity to aripiprazole.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
This medication is given as an injection once a month by your healthcare provider.,Do not try to inject yourself; it must be given by a healthcare professional.,After each injection, you will need to stay at the doctor's office or clinic for at least 2 hours to be monitored for any serious side effects.,You will need to take oral aripiprazole for 3 days before your first injection to see if you can tolerate the medication.,Common side effects include headache, insomnia, nausea, and injection site pain.,Seek emergency care if you have allergic reaction (hives, difficulty breathing, swelling), uncontrolled muscle movements, or thoughts of suicide.,Avoid alcohol and grapefruit juice while on this medication.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRISDELLE vs ABILIFY ASIMTUFII, answered by our medical review team.
BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. ABILIFY ASIMTUFII is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRISDELLE and ABILIFY ASIMTUFII depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. The standard adult dose of ABILIFY ASIMTUFII is: Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRISDELLE and ABILIFY ASIMTUFII in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. ABILIFY ASIMTUFII is classified as Category C. Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Adv. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.